The Antidepressant Sertraline Provides a Promising Therapeutic Option for Neurotropic Cryptococcal Infections
Антидепрессант сертралин как перспективный терапевтический препарат при нейротропных криптококковых инфекциях
2012-04-17
SCID: 54.1/qe4tf79s
Discuss with AI
Cryptococcus neoformanscentral nervous system fungal infectioninhibition of fungal protein synthesissertraline (Zoloft)synergy with fluconazole
Figures from the paper
Abstract (AI)
Therapeutic treatment for systemic mycoses is severely hampered by the extremely limited number of antifungals. The difficulty of treatment of fungal infections in the central nervous system is further compounded by the poor central nervous system (CNS) penetration of most antifungals due to the blood-brain barrier. Only a few fungistatic azole drugs, such as fluconazole, show reasonable CNS penetration. Here we demonstrate that sertraline (Zoloft), the most frequently prescribed antidepressant, displays potent antifungal activity against Cryptococcus neoformans, the major causative agent of fungal meningitis. In in vitro assays, this neurotropic drug is fungicidal to all natural Cryptococcus isolates tested at clinically relevant concentrations. Furthermore, sertraline interacts synergistically or additively with fluconazole against Cryptococcus. Importantly, consistent with our in vitro observations, sertraline used alone reduces the brain fungal burden at an efficacy comparable to that of fluconazole in a murine model of systemic cryptococcosis. It works synergistically with fluconazole in reducing the fungal burden in brain, kidney, and spleen. In contrast to its potency against Cryptococcus, sertraline is less effective against strains of Candida species and its interactions with fluconazole against Candida strains are often antagonistic. Therefore, our data suggest the unique application of sertraline against cryptococcosis. To understand the antifungal mechanisms of sertraline, we screened a whole-genome deletion collection of Saccharomyces cerevisiae for altered sertraline susceptibility. Gene ontology analyses of selected mutations suggest that sertraline perturbs translation. In vitro translation assays using fungal cell extracts show that sertraline inhibits protein synthesis. Taken together, our findings indicate the potential of adopting this antidepressant in treating cryptococcal meningitis.
Key Findings
1
Genetic screening in Saccharomyces cerevisiae and gene ontology analysis indicate sertraline perturbs translation.
2
In a murine systemic cryptococcosis model, sertraline alone reduced brain fungal burden with efficacy comparable to fluconazole.
3
In vitro translation assays using fungal extracts demonstrate that sertraline inhibits protein synthesis.
4
Sertraline acts synergistically or additively with fluconazole against Cryptococcus, enhancing antifungal effects.
5
Sertraline combined with fluconazole synergistically reduced fungal burden in brain, kidney, and spleen in mice.
6
Sertraline exhibits potent fungicidal activity against all tested natural Cryptococcus neoformans isolates at clinically relevant concentrations in vitro.
7
Sertraline is less effective against Candida species and often shows antagonistic interactions with fluconazole against Candida strains.
Research Object
Sertraline as an antifungal agent against Cryptococcus neoformans (neurotropic cryptococcal infection) in vitro and in murine systemic/brain infection models
Research Subject
Antifungal efficacy and interactions (fungicidal activity, reduction of brain/kidney/spleen fungal burden, synergy/additivity with fluconazole) and mechanism of action (inhibition of fungal protein translation) of sertraline against Cryptococcus
Publication Details
Publication Date
2012-04-17
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest